Adam Sikora

BIBF 1120 w terapii angiogennej nowotworów



BIBF 1120 in antiangiogenic therapy of cancer

Inhibition of tumor – related angiogenesis has become an attractive target for antcancer therapy. Antiangiogenic strategy includes: monoclonal antibodies against vascular endothelial growth factor (VEGF) and its receptor (VEGFR), small molecule inhibitors of VEGF tyrosine kinase activity, VEGF Trap and a new class named “vascular disrupting agents”, tested ongoing clinical trials which will further define their role in management of NSCLC and others. BIBF 1120 is an investigational orally administrated receptor tyrosine knase inhibitor that has shown antiangiogenic and antineoplastic activity, inhibiting VEGFR, plated-derived growth factor receptor (PDGF) and fibroblast growth factor (FGF) receptor tyrosine kinases, preventing tumor growth and interfering with the angiogenesis – signaling cascade and overcoming drug resistances.

Keywords: angiogenesis, oral antiangiogenic agents, VEGF, PDGFR, FGF, BIBF 1120.

© Farm Pol, 2014, 70(5): 235-239